Document:

EX-10.6

 Exhibit 10.6 

___________, 2021 
 LifeSci Acquisition III Corp. 

250 W. 55th Street, #3401 
 New York, NY 10019 

Ladies and Gentlemen: 
 LifeSci Acquisition III
Corp. (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”), intends to register its securities under the Securities Act of 1933, as amended
(“Securities Act”), in connection with its initial public offering (“IPO”), pursuant to a registration statement on Form S-1 (“Registration Statement”). 

The undersigned hereby commits that it will purchase an aggregate of 3,033,333 warrants of the Company (“Private Warrants”), at a
price of $0.90 per warrant for an aggregate purchase price of $2,730,000 (the “Private Warrant Purchase Price”). 
 At least
twenty-four (24) hours prior to the effective date of the Registration Statement, the undersigned will cause the Private Warrant Purchase Price to be delivered to Loeb & Loeb, LLP (“Loeb”), as escrow agent, by wire transfer
as set forth in the instructions attached as Exhibit A to hold in a non-interest bearing account until the Company consummates the IPO. 

The consummation of the purchase and issuance of the Private Warrants shall occur simultaneously with the consummation of the IPO.
Simultaneously with the consummation of the IPO, Continental shall deposit the Private Warrant Purchase Price, without interest or deduction, into the trust fund (“Trust Fund”) established by the Company for the benefit of the
Company’s public stockholders as described in the Registration Statement. 
 Each of the Company and the undersigned acknowledges and
agrees that Loeb is serving hereunder solely as a convenience to the parties to facilitate the purchase of the Private Warrants. 

Additionally, the undersigned agrees: 
  

	 	•	 	 not to propose, or vote in favor of, an amendment to the Company’s Amended and Restated Certificate of
Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of the Company’s shares of Common Stock sold in the IPO if the Company does not complete an initial Business Combination within 24 months
from the closing of the IPO, unless the Company provides the holders of shares of Common Stock sold in the IPO with the opportunity to redeem their shares of Common Stock upon approval of any such amendment at a
per-share price, payable in cash, equal to the aggregate amount of the Trust Fund, including interest earned on Trust Fund and not previously released to the Company to pay the Company’s franchise and
income taxes, divided by the number of then outstanding shares of Common Stock sold in the IPO; 

  

	 	•	 	 the undersigned will not participate in any liquidation distribution with respect to the Private Warrants (but
will participate in liquidation distributions with respect to any shares of Common Stock purchased by the undersigned in the IPO or in the open market) if the Company fails to consummate a Business Combination; 

	 	•	 	 that the Private Warrants and underlying securities will not be transferable until after the consummation of a
Business Combination except (i) to the Company’s pre-IPO stockholders, or to the Company’s officers, directors, advisors and employees, (ii) transfers to the undersigned’s affiliates
or its members upon its liquidation, (iii) to relatives and trusts for estate planning purposes, (iv) by virtue of the laws of descent and distribution upon death, (v) pursuant to a qualified domestic relations order, (vi) by
private sales at prices no greater than the price at which the Private Warrants were originally purchased or (vii) to the Company for cancellation in connection with the consummation of a Business Combination, in each case (except for clause
vii) where the transferee agrees to the terms of the transfer restrictions; and 

  

	 	•	 	 the Private Warrants will include any additional terms or restrictions as is customary in other similarly
structured blank check company offerings or as may be reasonably required by the underwriters in the IPO in order to consummate the IPO, each of which will be set forth in the Registration Statement. 

The undersigned acknowledges and agrees that the purchaser of the Private Warrants will execute agreements in form and substance typical for
transactions of this nature necessary to effectuate the foregoing agreements and obligations prior to the consummation of the IPO as are reasonably acceptable to the undersigned, including but not limited to an insider letter. 

The undersigned hereby represents and warrants that: 

(a) it has been advised that the Private Warrants have not been registered under the Securities Act; 

(b) it will be acquiring the Private Warrants for its account for investment purposes only; 

(c) it has no present intention of selling or otherwise disposing of the Private Warrants in violation of the securities laws of the United
States; 
 (d) it is an “accredited investor” as defined by Rule 501 of Regulation D promulgated under the Securities Act of 1933,
as amended; 
 (e) it has had both the opportunity to ask questions and receive answers from the officers and directors of the Company and
all persons acting on its behalf concerning the terms and conditions of the offer made hereunder; 
 (f) it is familiar with the proposed
business, management, financial condition and affairs of the Company; 

  
 2 

 (g) it has full power, authority and legal capacity to execute and deliver this letter and
any documents contemplated herein or needed to consummate the transactions contemplated in this letter; and 
 (h) this letter constitutes
its legal, valid and binding obligation, and is enforceable against it. 
 This letter agreement constitutes the entire agreement between
the undersigned and the Company with respect to the purchase of the Private Warrants, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to the same. 

 

			
	Very truly yours,
	
	LIFESCI HOLDINGS LLC
		
	By:	 	          

		 	Name:
		 	Title:

  

			
	Accepted and Agreed:
	
	LIFESCI ACQUISITION III CORP.
		
	By:	 	  

		 	Name: Andrew McDonald
		 	Title: Chief Executive Officer

  
 3 

 Exhibit A 

Wire InstructionsEX-10.7

 Exhibit 10.7 

LIFESCI ACQUISITION III CORP. 

250 W. 55th St., #3401 
 New York,
NY 10019 
 _____, 2021 
 LifeSci Capital LLC

 250 W. 55th St., #3401 
 New York, NY 10019 

Ladies and Gentlemen: 
 This letter will confirm
our agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration Statement”) for the initial public offering (the
“IPO”) of the securities of LifeSci Acquisition Corp. (the “Company”) and continuing until the earlier of (i) the consummation by the Company of an initial business combination or (ii) the
Company’s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”), LifeSci Capital LLC (“LC”) shall make
available to the Company certain office space, secretarial and administrative services as may be required by the Company from time to time, situated at 250 W. 55th St., #3401, New York, NY 10019 (or any successor location). In exchange therefore,
the Company shall pay LC a sum not to exceed $10,000 per month, respectively, on the Effective Date and continuing monthly thereafter until the Termination Date. LC hereby agrees that it does not have any right, title, interest or claim of any kind
in or to any monies that may be set aside in a trust account (the “Trust Account”) that may be established by the Company for the benefit of the Company’s public stockholders upon the consummation of the IPO as described
in the Registration Statement ( “Claim”) and hereby waives any Claim it may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with the Company and will not seek recourse against
the Trust Account for any reason whatsoever. 
  

			
	Very truly yours,
	
	LIFESCI ACQUISITION III CORP.
		
	By:	 	  

	Name:	 	Andrew McDonald
	Title:	 	Chief Executive Officer

  

			
	AGREED TO AND ACCEPTED BY:
	
	LIFESCI CAPITAL LLC
		
	By:	 	  

	Name:	 	Andrew McDonald
	Title:	 	Chief Executive OfficerDocument

EXHIBIT 10.3
May 20, 2021

John Burkart    
Pleasanton, CA 

Dear John,

We are pleased to offer you employment with Welltower Inc., subject to your acceptance of this offer on or before Friday, May 28, 2021.  This offer is contingent upon successful completion of our customary screening process as detailed below. The terms of the offer are as follows:
1.Title and Responsibilities.  Chief Operating Officer to be based in our Dallas, TX office. The Chief Operating Officer will be responsible for the overall strategy and results of our Outpatient Medical group and Asset Management function to include but not limited to capital expenditures, marketing strategies, revenue management, and to drive value to the bottom line in our residential business.  This role will include being an inspiring thought leader who thrives on the diversity of teams to deliver synergistic results, mentoring and growing talent along the way.  The Chief Operating Officer provides the leadership, management, and vision necessary to ensure that the company has the proper operational and administrative controls in place to effectively grow the organization and to ensure financial strength and operating efficiency. You will report to Shankh Mitra.

2.Start Date.  Monday, July 19, 2021.

3.Compensation.  Starting annual base salary for full-time employment will be $600,000 per year.  Future adjustments to base salary will be subject to annual review by Welltower’s senior management and will be pro-rated for the partial year 2021.

4.Short-term Incentive.  You will be eligible for an annual short-term incentive based on a combination of Company and individual performance factors.  The target bonus for this position is 125% of base salary, pro-rated for the partial year 2021.

5.Long-term Incentive. You will receive a long-term incentive award on or about your start date with entry into Welltower’s 2021-2023 Long-Term Incentive Program, pro-rated for the partial year 2021.  Thirty percent of the award will be issued in restricted stock units will vest over four years with the first vesting date of January 15, 2022. The remaining seventy percent will be issued as performance stock units based on a three-year forward-looking performance period that began on January 1, 2021 and ends on December 31, 2023. The LTIP is governed by detailed program guidelines and terms, which will be provided for your review.

Throughout your employment you will be entered into subsequent three-year programs, beginning in February 2022, with a target award of $2,000,000. 

6.Benefit Program.  You will be entitled to participate in all Welltower benefit programs commensurate with other Welltower employees, including health, life and disability programs, and in Welltower’s 401(k) plan, subject to your satisfaction of any eligibility criteria. As detailed in Welltower’s Employee Handbook you are eligible to participate in the medical, dental, vision, life insurance and disability plans on the thirty-first (31st) day of employment.

7.Paid Time Off.  You will receive twenty-four (24) days of paid time off (PTO) annually, pro-rated for the partial year 2021.  PTO days are in addition to annual Company holidays. Additional paid time off in future years will be granted subject to the Welltower PTO policy.

8.Successful Completion of Pre-Employment Screenings.  The offer contained in this letter is subject to your satisfactory completion of the Company’s mandatory background screening, reference check, 

and drug screening within five business days of the offer acceptance date. Additionally, you must provide confirmation of your status as a United States citizen or permanent resident satisfactory of the company.  If any of these background checks or screenings are not satisfactory to the Company in its sole discretion or completed in the prescribed time frame, the Company may rescind its offer.

9.Additional Agreements. You will be provided at the time your LTIP grant is made our Confidential Information, Non-Disparagement, Non-Solicitation and Non-Competition Agreement to review and execute through Fidelity.

10.Compliance with Agreements.  You acknowledge that you are not subject to any restrictions, contractual or otherwise, that could impair your ability to fulfill the terms of this offer and your employment by the Company.  You have no business or personal relationships that would constitute a “conflict of interest.”

11.Employment-at-Will.  You will be an employee-at-will.

John, we are excited about having you join our team.  If you have any questions or comments, please feel free to call us.
Assuming this offer is acceptable to you, please indicate your acceptance by signing the enclosed copy of this letter and returning it via email.
Very truly yours,

WELLTOWER INC.    Accepted By:

/s/Pamela Byrne        /s/John Burkart    
Pamela Byrne    John Burkart
Senior Vice President, Head of Human Capital 

Dated:    May 20, 2021        Dated: May 20, 2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]